scispace - formally typeset
G

Gordon L. Amidon

Researcher at University of Michigan

Publications -  469
Citations -  38521

Gordon L. Amidon is an academic researcher from University of Michigan. The author has contributed to research in topics: Intestinal absorption & Prodrug. The author has an hindex of 86, co-authored 466 publications receiving 35880 citations. Previous affiliations of Gordon L. Amidon include ETH Zurich & Merck & Co..

Papers
More filters
Journal ArticleDOI

The biowaiver extension for BCS class III drugs: The effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation

TL;DR: The results of GastroPlus simulations indicate that the dissolution rate of BCS class III drugs could be prolonged to the point where dissolution, rather than permeability, would control the overall absorption.
Journal ArticleDOI

Excess free energy approach to the estimation of solubility in mixed solvent systems I: Theory

TL;DR: An approach is developed by which the solubility of an organic compound in mixed solvents may be estimated by using an expression for the excess Gibbs free energy of mixing for multicomponent solvent systems to obtain parameters characteristic of the interaction between thesolvents.
Journal ArticleDOI

Permeability dominates in vivo intestinal absorption of P-gp substrate with high solubility and high permeability.

TL;DR: The data suggest that P- gp plays a minimal role in the in vivo intestinal absorption process of verapamil with high water solubility and high membrane permeability, and does not undermine the importance of P-gp in oral drug bioavailability, drug disposition from the liver, drug efflux from the blood-brain barrier, and drug-drug interaction.
Journal ArticleDOI

Pharmacokinetics of Trimethoprim and Sulfamethoxazole in Normal Subjects and in Patients with Renal Failure

TL;DR: A dosage regimen involving reduced doses of both drugs, with an interval between doses of approximately 12 hr, is proposed for patients with severe renal failure.
Journal ArticleDOI

Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability.

TL;DR: Dipeptide monoester prodrugs of floxuridine suggest their potential for increased oral uptake, delayed enzymatic bioconversion and enhanced resistance to metabolism to 5-fluorouracil, as well as enhanced uptake and cytotoxic activity in cancer cells, attributes that would facilitate prolonged systemic circulation for enhanced therapeutic action.